• Theralase Technologies (TSXV:TLT) has been approved for a clinical study to treat bladder cancer
  • The study will focus on patients with Stage 0 carcinomas, who are resistant to conventional treatment.
  • Theralase now has four sites open for patient enrolment and treatment, and 16 clinical study sites
  • Theralase Technologies (TLT) is up 11.54 per cent, with shares currently trading at $0.29

Pharmaceutical company Theralase Technologies (TSXV:TLT) has announced the approval of a clinical study for treating bladder cancer. 

Theralase received the approval for Phase II of the study from the Nova Scotia Health Authority (NSHA) Research Ethics Board.

The study will treat patients with Stage 0 carcinomas, who are unresponsive to BCG Therapy, which is commonly used to treat the disease.

BCG, or Bacillus Calmette Guerin vaccine, originally treated tuberculosis. It is now used to stop or delay bladder cancer growth.

Dr Ricardo Rendon, MD, FRCSC, is a Professor at the Dalhousie University of Medicine and Director of the clinical trial. The Urology Department at Dalhousie specialises in bladder cancer research.

“We are excited to work with Theralase for the NMIBC clinical trial. Tackling cancer is a crucial topic and a priority for this region.

“I am pleased that NSHA is able to contribute to the growth of innovative cancer research by taking part in this leading Pivotal PhotoDynamic Therapy study,” Rendon said.

With the addition of NSHA, Theralase now has four sites open for the enrolment and treatment of patients. These include NSHA, the London Health Science Centre, the University Health Network, and the McGill University Health Centre. 

Theralase also has approximately 16 clinical study sites in Canada and the U.S.

Company CEO Shawn Shirazi, Ph.D., stated that ten patients have been treated in study thus far.

“By continuing to advance Study II, we hope to bring this treatment to all Canadian patients suffering from this disease. We look forward to starting our clinical study in the U.S., subject to regulatory approval,” Shirazi said.

Theralase Technologies (TLT) is up 11.54 per cent, with shares currently trading for $0.29 at 12:04pm EST.

More From The Market Online

Revolutionizing medical imaging with nanocarbon-based contrast drugs

The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM) is transforming carbon capture and reuse technology.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

Theralase enhances cancer drug efficacy

Theralase Technologies (TSXV:TLT) announces its Ruvidar compound creates a new compound able to significantly kill more cancer cells.

FDA committee rejects MDMA drug, discounting psychedelic stocks

A committee of the U.S. FDA rejects a drug application to treat PTSD using MDMA-assisted therapy, causing numerous stocks to fall.